Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 12/20 | 0.52 |
| ▸ | FLT4 | P35916 | 12/20 | 0.52 |
| ▸ | KDR | P35968 | 12/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619056 | 1.00 | FLT1 (0.52) | FLT1FLT4KDRESR1PTGES2 | |
| SCHEMBL4620421 | 0.90 | FLT1 (0.53) | FLT1FLT4KDRESR1PTGES2 | |
| SCHEMBL4620428 | 0.90 | FLT1 (0.53) | FLT1FLT4KDRESR1PTGES2 | |
| SCHEMBL4619405 | 0.88 | FLT1 (0.59) | FLT1FLT4KDR | |
| SCHEMBL4619411 | 0.88 | FLT1 (0.59) | FLT1FLT4KDR | |
| SCHEMBL5409218 | 0.87 | AR (0.48) | FLT1FLT4KDRPTGES2MAPT | |
| SCHEMBL5409213 | 0.87 | AR (0.48) | FLT1FLT4KDRPTGES2MAPT | |
| SCHEMBL5417564 | 0.86 | FLT1 (0.53) | FLT1FLT4KDRKDM4EHTT | |
| SCHEMBL5417555 | 0.86 | FLT1 (0.53) | FLT1FLT4KDRKDM4EHTT | |
| SCHEMBL4620137 | 0.84 | FLT1 (0.53) | FLT1FLT4KDRPTGES2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | FLT1 4126/4885FLT4 4438/4885KDR 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.